Studie
Studien
| Studie | Patienten | Therapie | OS | Bemerkungen |
| GITSG (2) | 43 | Observation | 10% / 2a | p = 0,007 |
| 5-FU plus Radiotherapie | 20% / 2a | |||
| EORTC 40891 (3) | 218 | Observation | 26% / 2a | p = 0,10 |
| 5-FU plus Radiotherapie | 34% / 2a | |||
| ESPAC-1 (4) | 289 | Observation | 16,9 Monate | |
| Chemoradiotherapie | 13,9 Monate | |||
| 5-FU | 21,6 Monate | |||
| ChemoRadiotherapie plus 5-FU | 19,9 Monate | |||
| RTOG 9704 (5) | 451 | 5-FU plus Radiotherapie | 22% at 5 yr | p = 0,12 |
| Gemcitabine plus Radiotherapie | 18% at 5 yr |
Quelle
Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium .
IJROBP 75 (2009) 364-368
2.) Gastrointestinal Tumor Study Group:
Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer.
Cancer 59(12): 2006-2010, 1987.
3.) Klinkenbijl JH, et al.:
Adjuvant radiotherapy and 5-fluoro-uracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Ann Surg 230(1999):776-82.
4.) Neoptolemos JP, et al.:
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
N Engl J Med 350(2004):1200-10
5.) Regine WF, et al.: Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 18(2011):1319-26
